Search
Rozrolimupab
go.drugbank.com/drugs/DB05209InvestigationalRozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic
Temanogrel
go.drugbank.com/drugs/DB05227InvestigationalAPD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.
Tetrodotoxin
go.drugbank.com/drugs/DB05232InvestigationalAn aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order tetraodontiformes, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction. Tetrodotox...
Categories: Compounds used in a research, industrial, or household settingLGD2941
go.drugbank.com/drugs/DB05234ExperimentalLGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand and TAP.
ReN001
go.drugbank.com/drugs/DB05236InvestigationalReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke. … ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the treatment of stroke in humans
XL765
go.drugbank.com/drugs/DB05241InvestigationalXL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.
NUC B1000
go.drugbank.com/drugs/DB05242Experimentalthe RNAi response against a targeted disease causing gene. … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid
Oxypurinol
go.drugbank.com/drugs/DB05262InvestigationalOxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol.
iCo-007
go.drugbank.com/drugs/DB05268InvestigationaliCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis
SB-249553
go.drugbank.com/drugs/DB05285ExperimentalSB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. It is also under by GlaxoSmithKline to treat melanoma and lung cancer.